These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 27620370

  • 1. Predicting survival in node-positive prostate cancer after open, laparoscopic or robotic radical prostatectomy: A competing risk analysis of a multi-institutional database.
    Schiavina R, Bianchi L, Borghesi M, Briganti A, Brunocilla E, Carini M, Terrone C, Mottrie A, Dente D, Gacci M, Gontero P, Gurioli A, Imbimbo C, La Manna G, Marchioro G, Milanese G, Mirone V, Montorsi F, Morgia G, Munegato S, Novara G, Panarello D, Porreca A, Russo GI, Serni S, Simonato A, Urzì D, Verze P, Volpe A, Martorana G.
    Int J Urol; 2016 Dec; 23(12):1000-1008. PubMed ID: 27620370
    [Abstract] [Full Text] [Related]

  • 2. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L, Nini A, Bianchi M, Gandaglia G, Fossati N, Suardi N, Moschini M, Dell'Oglio P, Schiavina R, Montorsi F, Briganti A.
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [Abstract] [Full Text] [Related]

  • 3. Adverse Features and Competing Risk Mortality in Patients With High-Risk Prostate Cancer.
    Vagnoni V, Bianchi L, Borghesi M, Pultrone CV, Dababneh H, Chessa F, La Manna G, Rizzi S, Porreca A, Brunocilla E, Martorana G, Schiavina R.
    Clin Genitourin Cancer; 2017 Apr; 15(2):e239-e248. PubMed ID: 27641658
    [Abstract] [Full Text] [Related]

  • 4. Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era.
    Dorin RP, Lieskovsky G, Fairey AS, Cai J, Daneshmand S.
    Urol Oncol; 2013 Nov; 31(8):1441-7. PubMed ID: 22516714
    [Abstract] [Full Text] [Related]

  • 5. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G, Gallina A, Larcher A, Briganti A, Capitanio U, Suardi N, Lista G, Abrate A, Sangalli MN, Buffi N, Cestari A, Guazzoni G, Rigatti P, Montorsi F.
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [Abstract] [Full Text] [Related]

  • 6. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, Frank I, Blute ML.
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [Abstract] [Full Text] [Related]

  • 7. Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer.
    Boormans JL, Wildhagen MF, Bangma CH, Verhagen PC, van Leenders GJ.
    BJU Int; 2008 Dec; 102(11):1589-93. PubMed ID: 18710447
    [Abstract] [Full Text] [Related]

  • 8. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion.
    Preisser F, Bandini M, Marchioni M, Nazzani S, Tian Z, Pompe RS, Fossati N, Briganti A, Saad F, Shariat SF, Heinzer H, Huland H, Graefen M, Tilki D, Karakiewicz PI.
    Prostate; 2018 May; 78(6):469-475. PubMed ID: 29460290
    [Abstract] [Full Text] [Related]

  • 9. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy.
    Briganti A, Karnes JR, Da Pozzo LF, Cozzarini C, Gallina A, Suardi N, Bianchi M, Freschi M, Doglioni C, Fazio F, Rigatti P, Montorsi F, Blute ML.
    Eur Urol; 2009 Feb; 55(2):261-70. PubMed ID: 18838212
    [Abstract] [Full Text] [Related]

  • 10. Differing risk of cancer death among patients with lymph node metastasis after radical prostatectomy and pelvic lymph node dissection: identification of risk categories according to number of positive nodes and Gleason score.
    Schiavina R, Borghesi M, Brunocilla E, Manferrari F, Fiorentino M, Vagnoni V, Baccos A, Pultrone CV, Rocca GC, Rizzi S, Martorana G.
    BJU Int; 2013 Jun; 111(8):1237-44. PubMed ID: 23331345
    [Abstract] [Full Text] [Related]

  • 11. Intermediate-term cancer control outcomes in prostate cancer patients treated with robotic-assisted laparoscopic radical prostatectomy: a multi-institutional analysis.
    Abdollah F, Dalela D, Sood A, Sammon J, Jeong W, Beyer B, Fossati N, Rogers CG, Diaz-Insua M, Peabody J, Haese A, Montorsi F, Graefen M, Briganti A, Menon M.
    World J Urol; 2016 Oct; 34(10):1357-66. PubMed ID: 26873596
    [Abstract] [Full Text] [Related]

  • 12. Long-Term Mortality in Patients with Positive Lymph Nodes at the Time of Radical Prostatectomy.
    Froehner M, Koch R, Farahzadi S, Heberling U, Borkowetz A, Twelker L, Baretton GB, Wirth MP, Thomas C.
    Urol Int; 2019 Oct; 103(4):427-432. PubMed ID: 31661703
    [Abstract] [Full Text] [Related]

  • 13. Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy.
    von Bodman C, Godoy G, Chade DC, Cronin A, Tafe LJ, Fine SW, Laudone V, Scardino PT, Eastham JA.
    J Urol; 2010 Jul; 184(1):143-8. PubMed ID: 20478587
    [Abstract] [Full Text] [Related]

  • 14. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    Weckermann D, Goppelt M, Dorn R, Wawroschek F, Harzmann R.
    BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
    [Abstract] [Full Text] [Related]

  • 15. Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study.
    Preisser F, van den Bergh RCN, Gandaglia G, Ost P, Surcel CI, Sooriakumaran P, Montorsi F, Graefen M, van der Poel H, de la Taille A, Briganti A, Salomon L, Ploussard G, Tilki D, EAU-YAUWP.
    J Urol; 2020 Feb; 203(2):338-343. PubMed ID: 31437119
    [Abstract] [Full Text] [Related]

  • 16. Head-to-head comparison of lymph node density and number of positive lymph nodes in stratifying the outcome of patients with lymph node-positive prostate cancer submitted to radical prostatectomy and extended lymph node dissection.
    Passoni NM, Abdollah F, Suardi N, Gallina A, Bianchi M, Tutolo M, Fossati N, Gandaglia G, Salonia A, Freschi M, Rigatti P, Montorsi F, Briganti A.
    Urol Oncol; 2014 Jan; 32(1):29.e21-8. PubMed ID: 23490908
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Biochemical recurrence after robot-assisted extended pelvic lymphadenectomy for prostate cancer.
    Chenam A, Ruel N, Pal S, Barlog J, Lau C, Wilson T, Yuh B.
    Can J Urol; 2018 Jun; 25(3):9340-9348. PubMed ID: 29900823
    [Abstract] [Full Text] [Related]

  • 19. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
    Steuber T, Budäus L, Walz J, Zorn KC, Schlomm T, Chun F, Ahyai S, Fisch M, Sauter G, Huland H, Graefen M, Haese A.
    BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.